The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYK | +4.35% | +78.03% | +12.23% | +90,122% |
| S&P | +15.06% | +95.03% | +14.29% | +3,850% |
Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.02B | 11.1% |
| Gross Profit | $3.75B | 12.8% |
| Gross Margin | 62.27% | 1.0% |
| Market Cap | $151.20B | 16.6% |
| Market Cap / Employee | $2.85M | 0.0% |
| Employees | 53K | 1.9% |
| Net Income | $884.00M | 7.2% |
| EBITDA | $1.66B | 17.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.38B | 26.7% |
| Accounts Receivable | $3.92B | 8.2% |
| Inventory | 5.3K | 4.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.22B | 44.9% |
| Short Term Debt | $1.91B | -14.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.83% | -2.2% |
| Return On Invested Capital | 8.20% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $928.00M | 92.9% |
| Operating Free Cash Flow | $1.11B | 75.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 38.73 | 46.38 | 50.23 | 52.35 | 37.96% |
| Price to Book | 6.97 | 6.81 | 6.88 | 7.22 | 6.85% |
| Price to Sales | 6.34 | 6.15 | 6.20 | 6.42 | 4.69% |
| Price to Tangible Book Value | -15297.35 | -115.63 | 369.73 | -35.23 | -81.30% |
| Price to Free Cash Flow TTM | 69.44 | 61.29 | 61.42 | 55.13 | -31.73% |
| Enterprise Value to EBITDA | 102.05 | 77.14 | 109.43 | 101.11 | 0.88% |
| Free Cash Flow Yield | 1.4% | 1.6% | 1.6% | 1.8% | 46.47% |
| Return on Equity | 18.9% | 15.3% | 14.3% | 14.3% | -23.29% |
| Total Debt | $16.01B | $14.12B | $17.36B | $17.13B | 34.40% |
SYK earnings call for the period ending September 30, 2021.
SYK earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
